AKT1 and sarcoma: Such dual targeted approaches targeting mTOR and Akt [36], or mTOR and PI3K have proven to be pertinent in preclinical models [34] and one (targeting mTOR and IGFR-1) has reached the clinical phase in patients with advanced sarcomas and other solid tumors [35].